Study Shows Cannabis Use Linked to Lung Inflammation and Emphysema

Nov.23.2022
Study Shows Cannabis Use Linked to Lung Inflammation and Emphysema
Scientists at the University of Ottawa have found that marijuana users have more respiratory inflammation and signs of emphysema than smokers.

Research shows that the source of the lung lobe image is Global Look Press.


Scientists at the University of Ottawa have found that individuals who use marijuana have more signs of respiratory inflammation and lung emphysema in their lungs compared to smokers. This research was published in the Radiology journal.


Scientists analyzed the results of chest computed tomography (CT) scans from 56 cannabis users, 57 non-smokers, and 33 smokers. The data was obtained from October 2005 to July 2020 in Ottawa, Canada.


Compared to non-smokers, CT scans of marijuana users show differing frequencies of signs of respiratory inflammation, such as emphysema, bronchial thickening, bronchial dilation, mucous obstruction, and cardiac nodules.


Consumers of marijuana are 93% more likely to suffer from chronic obstructive pulmonary disease (COPD) compared to non-smokers, while smokers who consume marijuana have a 67% increased frequency of smoking.


A study has found that 38% of marijuana users who participated in the study reported experiencing gynecomastia, a condition that causes pathological breast enlargement in males. Of those affected, 16% were non-smokers.


This study has limitations, as it was not able to clearly distinguish the consequences of smoking from those of using marijuana. Firstly, only 28 out of 56 patients provided information about their daily marijuana intake, with an average of 1.85 grams per day.


Furthermore, out of 56 marijuana consumers, 50 of them also smoke. The author calls for further research.


Statement:


This article is compiled from third-party information and is intended for industry exchange and learning purposes only.


This article does not represent the views of 2FIRSTS and we cannot confirm the authenticity or accuracy of its content. The translation of this article is solely intended for industry-related research and communication.


Due to limitations in translation ability, the translated article may not fully reflect the original content. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign positions and statements.


Information compiled here is the property of the original media and authors. If there is any infringement, please contact us to request removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report|Virginia Vape Directory Shows Contrast Between Vuse and JUUL Pod Systems and CrossBar 20K, Loon Flavored Disposables
Special Report|Virginia Vape Directory Shows Contrast Between Vuse and JUUL Pod Systems and CrossBar 20K, Loon Flavored Disposables
A 2Firsts analysis of Virginia's liquid nicotine and vapor product certification directory identified 213 product records from 15 manufacturers. Companies associated with BAT, Altria, Imperial Brands, JTI and JUUL account for 127 entries. The directory also includes independent brands CrossBar 20K, Loon and Breeze. CrossBar advertises a 13mL disposable capable of up to 20,000 puffs, while Loon has 16 disposable entries featuring fruit, cooling and beverage-related flavors. Of all records, 120 are labeled as under FDA PMTA review. Virginia introduced revised penalties on October 1, 2026, including a minimum first-violation civil penalty of $5,000 per unlisted product, alongside new retail tobacco permitting requirements.
Regulations
Oct.30
Imperial Brands' NGP Revenue Rises 11.4% in FY2026 but Business Still Posts £63 Million Loss; Zone Reaches 114,000 US Stores as Smokeless Reporting Takes Shape
Imperial Brands' NGP Revenue Rises 11.4% in FY2026 but Business Still Posts £63 Million Loss; Zone Reaches 114,000 US Stores as Smokeless Reporting Takes Shape
Imperial Brands reported an 11.4% increase in next-generation product (NGP) net revenue to £419 million in fiscal 2026, while its adjusted NGP operating loss narrowed to £63 million. European NGP revenue rose 16.8%, while the Americas recorded a 17.1% decline. Global modern oral nicotine volumes increased 27.8%, with US nicotine pouch brand Zone expanding to approximately 114,000 stores. The company also acquired Black Buffalo in the US and Helwit in Sweden, broadening its oral nicotine portfolio. From FY2027, Imperial Brands will adopt a new Smokeless reporting category combining NGP with traditional oral tobacco. On the new basis, FY2026 Smokeless net revenue was £554 million, with adjusted operating profit of £14 million.
company
Nov.18
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Global PLC (NASDAQ: AIIR), a producer of flavored shisha tobacco and next-generation nicotine products, reported an 11.1% increase in third-quarter 2026 revenue to $99.8 million and a 7.7% rise in adjusted EBITDA to $30.9 million. Revenue for the first nine months increased 6.0% to $306.7 million, but the company posted a $74.2 million net loss, affected by listing-related expenses and other costs. Its New Growth Categories (NGC) business generated $2.1 million in nine-month revenue and an adjusted EBITDA loss of $10.8 million. AIR maintained its 2026 revenue growth guidance of 4%–6%, while lowering its capital expenditure outlook and raising its year-end leverage forecast from approximately 2.1 times to 2.5 times. The company has submitted a U.S. PMTA for its Crown Switch pod vape, with future contributions from new products dependent on regulatory progress and commercialization.
Capital Markets
Nov.13
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
Brad Rodu Says Declining Cigarette Smoking Is Key to Tobacco Harm Reduction | 2Firsts Interview
Brad Rodu Says Declining Cigarette Smoking Is Key to Tobacco Harm Reduction | 2Firsts Interview
After more than 30 years researching tobacco harm reduction, University of Louisville professor Brad Rodu says opposition to smoke-free alternatives still surprises him. In an exclusive 2Firsts interview in Manila, he argued that declining smoking rates represent progress even if nicotine use rises, discussed nicotine and cancer, and examined Sweden's snus experience and youth vaping. Rodu welcomed recent FDA decisions but criticized slow reviews and poor risk communication. He called a change in the WHO's stance potentially significant, while doubting it would happen soon.
Nov.20
EU TPD Revision May Slip to 2027: Parliament Backs Wider Nicotine Rules by 447 Votes as Commission Impact Assessment Reportedly Receives Negative Opinion
EU TPD Revision May Slip to 2027: Parliament Backs Wider Nicotine Rules by 447 Votes as Commission Impact Assessment Reportedly Receives Negative Opinion
On Nov 12, 2026, the European Parliament adopted a resolution on implementing Europe’s Beating Cancer Plan by 447 votes to 66, with 91 abstentions, urging the European Commission to speed up revisions to the Tobacco Products Directive (TPD) and Tobacco Advertising Directive (TAD). Parliament called for broader regulation of e-cigarettes, heated tobacco, nicotine pouches and other emerging nicotine products, proposing measures on packaging, health warnings, flavors, ingredient reporting, online age verification, digital marketing and premarket health impact assessments. EUNews and others reported that the Commission’s Regulatory Scrutiny Board (RSB) issued a negative opinion on the revisions’ impact assessment on Nov 9. The Commission had scheduled the initiative for December 2026, but the reported setback could push the legislative proposal into 2027. No revised official timetable has been announced, and Parliament’s resolution does not amend existing EU law.
Regulations
Nov.19